These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 10850318

  • 1. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH, Klutmann S, Jenicke L, Kröger S, Buchert R, Mester J, Clausen M.
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [Abstract] [Full Text] [Related]

  • 2. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
    Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M.
    J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
    [Abstract] [Full Text] [Related]

  • 3. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH, Klutmann S, Brenner W, Kröger S, Buchert R, Bleckmann C, Mester J, Henze E, Clausen M.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [Abstract] [Full Text] [Related]

  • 4. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH, Brenner W, Klutmann S, Hübner RH, Lassmann S, Feyerabend B, Lüttges J, Tinnemeyer S, Clausen M, Henze E.
    J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
    [Abstract] [Full Text] [Related]

  • 5. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model.
    Bohuslavizki KH, Klutmann S, Jenicke L, Brenner W, Feyerabend B, Henze E, Clausen M.
    Int J Radiat Oncol Biol Phys; 1999 Aug 01; 45(1):181-6. PubMed ID: 10477022
    [Abstract] [Full Text] [Related]

  • 6. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
    Bohuslavizki KH, Klutmann S, Bleckmann C, Brenner W, Lassmann S, Mester J, Henze E, Clausen M.
    Strahlenther Onkol; 1999 Feb 01; 175(2):57-61. PubMed ID: 10065139
    [Abstract] [Full Text] [Related]

  • 7. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
    Kutta H, Kampen U, Sagowski C, Brenner W, Bohuslavizki KH, Paulsen F.
    Strahlenther Onkol; 2005 Apr 01; 181(4):237-45. PubMed ID: 15827693
    [Abstract] [Full Text] [Related]

  • 8. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
    Torun N, Muratli A, Serim BD, Ergulen A, Altun GD.
    Curr Med Imaging Rev; 2019 Apr 01; 15(4):395-404. PubMed ID: 31989909
    [Abstract] [Full Text] [Related]

  • 9. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
    Ma C, Xie J, Chen Q, Wang G, Zuo S.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD007956. PubMed ID: 19821441
    [Abstract] [Full Text] [Related]

  • 10. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
    Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, Kim JS.
    Thyroid; 2008 Mar 07; 18(3):325-31. PubMed ID: 18341378
    [Abstract] [Full Text] [Related]

  • 11. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.
    Upadhyaya A, Zhou P, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z, Wang X, Zhang X, Zhang W.
    Nucl Med Commun; 2017 Nov 07; 38(11):891-903. PubMed ID: 28806348
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber P, Debus J, Karger CP.
    Int J Radiat Oncol Biol Phys; 2007 Mar 01; 67(3):651-9. PubMed ID: 17175118
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B, Huang R, Kuang A, Zhao Z, Zeng Y, Wang J, Tian R.
    Med Phys; 2011 Oct 01; 38(10):5412-9. PubMed ID: 21992360
    [Abstract] [Full Text] [Related]

  • 19. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
    Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, Vilardell M.
    J Nucl Med; 2001 May 01; 42(5):738-43. PubMed ID: 11337569
    [Abstract] [Full Text] [Related]

  • 20. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].
    Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Kalina S, Clausen M, Henze E.
    Nuklearmedizin; 1997 Apr 01; 36(3):103-9. PubMed ID: 9162904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.